N8 Medical N8 Medical
N8 Medical N8 Medical
  • Home
  • About Us
  • Leadership
  • News
  • Pipeline
  • Publications

N8 Medical News

N8 Medical > News > N8 Medical News

New Research Shows CSA-131 has Potent Antifungal Activity

July 12, 2016 7:56 pmNovember 7, 2017

A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and retains activity in various body fluids.

Read more

Colistin Resistance on the Rise

July 12, 2016 7:54 pmNovember 7, 2017

Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool available to treat multidrug resistant bacteria because bacteria were not exchanging genes for its resistance. Read more

CSA-131 Highly Effective against Colistin-resistant Strains

September 7, 2015 5:39 pmNovember 7, 2017

A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that CSA-131 is highly effective against Colistin resistant strains of Pseudomonas and Acinetobacter. 

Read more

Posts pagination

Previous 1 2

N8 Medical News

Here you will find the latest information, including: press releases, events and presentations and blog posts.

Newsletter Sign-up

Interested in hearing whats new with N8 Medical? Sign-up to join our newsletter.

Recent Posts

  • N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens
  • FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF
  • NIH Awards N8 Medical Two Additional SBIR Grants to Develop CeraShieldTM Coated Hemodialysis Catheters and Pedicle Screws
  • N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant
  • N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes

N8 Medical, LLC

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.
The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.
 
  • Home
  • Overview
  • Leadership
  • News
  • Technology
  • Pipeline
  • Publications

© 2019-2023 N8 Medical, LLC. All Rights Reserved. Privacy Policy

Menu
  • Home
  • About Us
  • Leadership
  • News
  • Pipeline
  • Publications